{"ticker": {"uuid": "2d51f6c2-5cb5-4af5-9a28-30a231af2d6a", "symbol": "SPRO", "name": "Spero Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Innovent licenses IBI355 rights to Spero for up to $1.1bn", "summary": "", "url": "https://finance.yahoo.com/m/4385de98-4d22-30fc-9295-2d9e6059552a/innovent-licenses-ibi355.html", "source_name": "Hospital Management", "published_at": "2026-07-15T10:01:36+00:00", "published_display": "15 Jul 2026 10:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals", "summary": "", "url": "https://finance.yahoo.com/m/a668a52a-493b-390d-b19c-26a9e84bfd61/j%26j-dips-despite-upbeat.html", "source_name": "BioPharma Dive", "published_at": "2026-07-15T09:18:00+00:00", "published_display": "15 Jul 2026 09:18", "sentiment": "negative", "sentiment_pct": 42, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics: \"Buy\" Utebzi Royalty Deal For Funding And SP001 In-Licensing (SPRO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOYWVTN1VXeFJsQ2ZVbktkcE8wZkhveGtMejQxbEdpX1ZPeUcweUNOaDlBajFvbnFqNlJMTlNlaXRZb1VkRGpwanpLN0dPQjVzSUVXcXIyN0ZGRDgyTW5SVkdoakM5N2dmX3kxYVlVUmxnelEyRmcyaHNjbDRRTUpEYWNDMTJNZlUxTm56OFRtbDdXTnZiamdsN0M1eW1JR3dRWHF6UUVFbzBodHd3a2xfbTlnNERlNFJ4a1E?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-14T17:40:33+00:00", "published_display": "14 Jul 2026 17:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero licenses anti-CD40L antibody from Innovent for $1.1bn", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNWTNwUjVJM3k4REcwT0Q5Rzh5VEJkOG4xYTZGWjRHb3lWd2prR1VMWkF6U3M0ajNXbE9zS0FEdTI4UnM4dmYzbTJwSFVGSU9fRERYUFdLdGJTUDMyd0VQZFFKbjRET3NUMkdQUWRZVmFlcTEwYy16MWNXSi12SXdydERlZEluSDhwU210SHRYWk9LYTFOeU9PNG9mZnp6N2pNb3ZzeW9JMU04UldGXzU3UENFaklqX19BUkVMajJmNWlidUZjeUxpSA?oc=5", "source_name": "Investing.com UK", "published_at": "2026-07-14T14:59:19+00:00", "published_display": "14 Jul 2026 14:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion", "summary": "Spero Therapeutics has licensed the rights to Innovent Biologics' experimental autoimmune disease treatment, IBI355, outside of Greater China in a deal potentially worth up to $1.1 billion. This agreement provides Spero with its first immunology asset, expanding beyond its infect", "url": "https://www.reuters.com/legal/litigation/spero-licenses-innovents-experimental-immune-disease-drug-up-11-billion-2026-07-14/", "source_name": "Reuters", "published_at": "2026-07-14T14:10:15", "published_display": "14 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero in-licenses Innovent\u2019s antibody therapy (SPRO:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOSENTeGlzOXRLMW1zS2FsT0dwZXB5UVVpaER0VlFqcmFvZm1mTG1tVFhhRHVjWkE4N3pxYm5mUlFFdVZEVGdWbjhXX25Lb2MtUUtFdmoyb1lxekFVaEc5SERiMHNvTDUyeFRnR0FicG9CclRLSGg2SFBEZHAwaXJoUmR6bEktWTVmdkE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-14T12:28:42+00:00", "published_display": "14 Jul 2026 12:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics (SPRO) Secures $105M Financing and $1.1B Licensing Agreement", "summary": "Spero Therapeutics (SPRO) announced a significant financing arrangement of $105 million with Healthcare Royalty and a licensing deal worth up to $1.1 billion with Innovent Biologics. These agreements aim to advance Spero's clinical programs, including the development of an antibo", "url": "https://www.gurufocus.com/news/8957684/spero-therapeutics-spro-secures-105m-financing-and-11b-licensing-agreement", "source_name": "GuruFocus", "published_at": "2026-07-14T13:10:15", "published_display": "14 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics (SPRO) Secures $105M Financing to Advance Immunology Development", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQZjRuc1NudFhGNUhTR1RmWE1LMEgwNUZuNU1WUnF0UGUtWHVLZU83cDB3VkE3SU9rUVRSUXFOSVNlSk45YmZuN1RKRlhFTGJoOHA3b2NKV0pBb2w4Mk1wdXh3TkhjeXUwaGY4dDhhMXpJLUtoX296U29tTk03azVkQU91RlVYX3hDVWtTbnZSSV9OcHg0SFI1cTZ2bDNrcUV5bmJYX3V3TFdEUGV0WUZyZWZjUXNMQlRoWl93?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-14T11:35:01+00:00", "published_display": "14 Jul 2026 11:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics (SPRO) Secures Exclusive License for SP001 Development", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPUG5HbU44TFhUNXk1clR5amZtUlRxQlhtbkhLb2RwMlBNNVR3dDRxZThhU1czMUFyc3o5SEhZc2k3dGNoOW1GRE1FbXFRZ3FZTUNEQXRoLUg4TDQ4cDhZdmktUW5feHVyTjVGRjJGQlBSakZPcHUwczdpYzdRSm14N3kwR0Vqd25yVjVqWXlRRlBQUEpuRmhGTm50N1lCc1V4OGRlY1Z4QnFxR2tqdG9V?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-14T11:35:01+00:00", "published_display": "14 Jul 2026 11:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics (SPRO) Secures Exclusive License for IBI355", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQdXJ5UlpsZjczUjBvZHNGcFd2OHNRaExTem4wV21sazhlQWUtZEhIUzVDbFpCc09ySmxsb0J6bE9TV2NKVmJ3MjVrWmctbVRVWGhCbWViekhkX1E0SG9GNWsxY3ZYdFFLT3ZqVDNJR3prbUNZTERHX2ZIU3JfaU1lNC1PNzRpZGhmd3pLQ0tHU2Q2NnV5UWVJbUFycll6ejNV?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-14T11:35:01+00:00", "published_display": "14 Jul 2026 11:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics Secures $105 Million Royalty Financing to Advance Immunology Pipeline", "summary": "Spero Therapeutics has secured $105 million in non-dilutive royalty financing from Healthcare Royalty (HCRx) to fund the clinical development of its lead immunology drug candidate, SP001. This financing, backed by future payments from its antibiotic Utebzi, enables Spero to exten", "url": "https://www.citybiz.co/article/873645/spero-therapeutics-secures-105-million-royalty-financing-to-advance-immunology-pipeline/", "source_name": "citybiz", "published_at": "2026-07-14T12:10:15", "published_display": "14 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics Licenses Immunology Drug Candidate From Innovent, Recieves $105 Million Financing", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/spero-therapeutics-licenses-immunology-drug-104640732.html", "source_name": "MT Newswires", "published_at": "2026-07-14T10:46:40+00:00", "published_display": "14 Jul 2026 10:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics Lands $105 Million Royalty Financing to Advance SP001 Development (SPRO)", "summary": "", "url": "https://finance.yahoo.com/m/9bb9d86a-52ae-3aef-bb4b-f7cd3fd578b3/spero-therapeutics-lands-%24105.html", "source_name": "InvestorsHub", "published_at": "2026-07-14T10:46:23+00:00", "published_display": "14 Jul 2026 10:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics Secures $105 Million Royalty Financing to Advance SP001 and Extend Cash Runway Through Second Half of 2029", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxPU2xmcmF2a2JwSWtNa2Z0WVRVOU4tdDc4NVJ6NFExbWpUZHZCMlZZaHlYTkVYcWFYeVc4RFgycnhxOW9CYVFmWDhHUFpDLTl3TFJORW9CdXZRcE5hQ1hVOEZ6cXM5bmdxRnBJdlBra0ZHdXgtZkZEUTZrbEpreDd5bWRydWhyaTJ0YmVpZ3pCRDBqWGxLZE5zZDNWNEVzX3A4bWxDdlVqNmZCMXpKRHhjS3NNbXZRTk9YbVpjckRNVEhXclZHd3NtcU4yRnhIMlRXMGNWVEIyeDNoSUpNRGw2ZkhJQnZGSFJNQ2RGMmtaUTRHQQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-14T10:12:00+00:00", "published_display": "14 Jul 2026 10:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/spero-therapeutics-announces-105-million-100200242.html", "source_name": "GlobeNewswire", "published_at": "2026-07-14T10:02:00+00:00", "published_display": "14 Jul 2026 10:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/innovent-biologics-spero-therapeutics-announce-100000421.html", "source_name": "PR Newswire", "published_at": "2026-07-14T10:00:00+00:00", "published_display": "14 Jul 2026 10:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics (Nasdaq: SPRO) inks SP001 deal and $105M royalty financing", "summary": "Spero Therapeutics has announced two significant financial and strategic moves: an exclusive worldwide licensing agreement (excluding Greater China) with Innovent Biologics for SP001, a third-generation Fc-silent anti-CD40L monoclonal antibody for which Spero paid a $35 million u", "url": "https://www.stocktitan.net/sec-filings/SPRO/8-k-spero-therapeutics-inc-reports-material-event-a86537e543f0.html", "source_name": "Stock Titan", "published_at": "2026-07-14T10:30:46", "published_display": "14 Jul 2026 10:30", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics shares fall after $105M KKR deal By Investing.com", "summary": "Spero Therapeutics shares dropped about 12% in pre-market trading after announcing a $105 million licensing agreement with affiliates of Healthcare Royalty, a KKR business. Under the deal, HCRx will receive a portion of future milestone and royalty payments from Utebzi sales, wit", "url": "https://ng.investing.com/news/stock-market-news/spero-therapeutics-shares-fall-after-105m-kkr-deal-93CH-2598306", "source_name": "Investing.com Nigeria", "published_at": "2026-07-14T10:24:46", "published_display": "14 Jul 2026 10:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics shares fall after $105M KKR deal", "summary": "Spero Therapeutics (SPRO) shares dropped by approximately 12% following the announcement of a $105 million licensing agreement with KKR's Healthcare Royalty business. Under the deal, HCRx will receive milestone and royalty payments from sales of Spero's drug Utebzi in exchange fo", "url": "https://www.investing.com/news/stock-market-news/spero-therapeutics-shares-fall-after-105m-kkr-deal-93CH-4790226", "source_name": "Investing.com", "published_at": "2026-07-14T10:10:15", "published_display": "14 Jul 2026 10:10", "sentiment": "negative", "sentiment_pct": 30, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero's $105M deal will support Phase 2 immunology drug SP001", "summary": "Spero Therapeutics has secured a $105 million non-recourse, non-dilutive royalty financing from Healthcare Royalty (HCRx) to fund the Phase 2 development of its lead immunology drug candidate, SP001. This financing, backed by a portion of future milestones and royalties from Uteb", "url": "https://www.stocktitan.net/news/SPRO/spero-therapeutics-announces-105-million-non-recourse-non-dilutive-yq6toa5chbcx.html", "source_name": "Stock Titan", "published_at": "2026-07-14T10:01:46", "published_display": "14 Jul 2026 10:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody", "summary": "Spero Therapeutics and Innovent Biologics have announced an exclusive licensing agreement for SP001 (IBI355), a third-generation anti-CD40L antibody. Spero receives global rights excluding Greater China and plans to initiate a Phase 2 trial for IgG4-related disease in Q2 2027. In", "url": "https://www.globenewswire.com/news-release/2026/07/14/3326657/0/en/spero-therapeutics-and-innovent-biologics-announce-exclusive-license-for-sp001-ibi355-a-phase-2-ready-third-generation-anti-cd40l-antibody.html", "source_name": "GlobeNewswire", "published_at": "2026-07-14T09:59:46", "published_display": "14 Jul 2026 09:59", "sentiment": "positive", "sentiment_pct": 94, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cambridge biotech strikes $1.1B deal with Chinese partner, shifts to immunology", "summary": "Cambridge-based Spero Therapeutics has signed a $1.1 billion drug deal with Chinese partner Innovent Biologics. This agreement will enable Spero to shift its strategic focus towards immunology. The company is leveraging proceeds from a recent drug approval to fund this new direct", "url": "https://www.bizjournals.com/boston/news/2026/07/14/spero-innovent-immunology-deal.html", "source_name": "The Business Journals", "published_at": "2026-07-14T09:59:46", "published_display": "14 Jul 2026 09:59", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Enterprise value to EBIT forward of Spero Therapeutics, Inc. \u2013 MUN:2HA", "summary": "This article provides financial data for Spero Therapeutics, Inc. (MUN:2HA), specifically focusing on its enterprise value to EBIT forward. It indicates that the market was closed with no trades at the time of publication. The content is presented within the TradingView platform,", "url": "https://www.tradingview.com/symbols/MUN-2HA/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T20:10:43", "published_display": "12 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics outlines its antibiotic pipeline as investors track regulatory progress", "summary": "Spero Therapeutics is a clinical-stage biopharmaceutical company focusing on novel antibiotic candidates for multidrug-resistant bacterial infections. The company's strategy involves progressing assets through clinical trials, considering potential collaborations, and navigating ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/spero-therapeutics-outlines-its-antibiotic-pipeline-as-investors-track/69716226", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T17:42:36", "published_display": "07 Jul 2026 17:42", "sentiment": "positive", "sentiment_pct": 67, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kailera Therapeutics Appoints Kathleen\u00a0Tregoning as Chief Corporate Affairs Officer", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/kailera-therapeutics-appoints-kathleen-tregoning-113000007.html", "source_name": "GlobeNewswire", "published_at": "2026-06-29T11:30:00+00:00", "published_display": "29 Jun 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics, Inc. Actuals & Estimates (NASDAQ:SPRO)", "summary": "This article provides an overview of Spero Therapeutics, Inc. (SPRO) stock, including its current price, historical performance, analyst forecasts, and key financial metrics. It highlights recent stock changes, market capitalization, upcoming earnings, and past financial results,", "url": "https://www.tradingview.com/symbols/NASDAQ-SPRO/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T16:10:41", "published_display": "26 Jun 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics, Inc. Actuals & Estimates (BOATS:SPRO)", "summary": "This article provides financial actuals and estimates for Spero Therapeutics, Inc. (SPRO), including analyst forecasts, historical price data, earnings reports, and other key financial metrics. It highlights that analysts expect a maximum and minimum price of $4.00, and the compa", "url": "https://www.tradingview.com/symbols/BOATS-SPRO/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T08:40:59", "published_display": "26 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics (NASDAQ: SPRO) doubles share authorization and adopts 2026 stock plan", "summary": "Spero Therapeutics' stockholders approved a new 2026 Stock Incentive Plan covering up to 12,895,866 shares and doubled the authorized common stock from 120,000,000 to 240,000,000 shares. These actions provide the company with greater flexibility for future equity awards and poten", "url": "https://www.stocktitan.net/sec-filings/SPRO/8-k-spero-therapeutics-inc-reports-material-event-38630813b4e4.html", "source_name": "Stock Titan", "published_at": "2026-06-26T05:40:56", "published_display": "26 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics (SPRO) grants director RSUs and 20,000 stock options", "summary": "Spero Therapeutics director Frank E. Thomas received equity awards comprising 10,000 restricted stock units (RSUs) and options to purchase 20,000 shares of common stock at an exercise price of $2.15 per share. Both the RSUs and options are set to vest on June 23, 2027, contingent", "url": "https://www.stocktitan.net/sec-filings/SPRO/form-4-spero-therapeutics-inc-insider-trading-activity-13ea138c3d4e.html", "source_name": "Stock Titan", "published_at": "2026-06-26T04:09:49", "published_display": "26 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics (SPRO) director receives RSU and 20,000-share option grant", "summary": "Spero Therapeutics director John C. Pottage Jr. was granted 10,000 restricted stock units (RSUs) and a stock option for 20,000 shares, as detailed in a recent Form 4 filing. The RSUs and stock options are set to vest on June 23, 2027, contingent upon his continued service as a di", "url": "https://www.stocktitan.net/sec-filings/SPRO/form-4-spero-therapeutics-inc-insider-trading-activity-63463829320b.html", "source_name": "Stock Titan", "published_at": "2026-06-26T04:09:49", "published_display": "26 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Spero Therapeutics Inc For: 25 June By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Spero Therapeutics Inc. related to activity on June 25th. It is a brief, factual announcement without further details provided within the content. The article primarily serves as a placeholder for a financial filing a", "url": "https://uk.investing.com/news/stock-market-news/form-4-spero-therapeutics-inc-for-25-june-93CH-4745517", "source_name": "Investing.com UK", "published_at": "2026-06-26T00:02:00", "published_display": "26 Jun 2026 00:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics (SPRO) director awarded RSUs and stock options", "summary": "Spero Therapeutics director Patrick V.J.J. Vink was granted 10,000 restricted stock units (RSUs) and options for 20,000 shares, as detailed in a recent SEC Form 4 filing. The RSUs and stock options vest on June 23, 2027, with the options having an exercise price of $2.15 per shar", "url": "https://www.stocktitan.net/sec-filings/SPRO/form-4-spero-therapeutics-inc-insider-trading-activity-a043c72cc825.html", "source_name": "Stock Titan", "published_at": "2026-06-25T23:40:50", "published_display": "25 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics (SPRO) director receives 10,000 RSUs and 20,000-share option grant", "summary": "Spero Therapeutics director Cynthia Smith was granted 10,000 Restricted Stock Units (RSUs) and a stock option for 20,000 shares of common stock. These equity awards, with an exercise price of $2.15 per share for the options, are compensation-related and will vest on June 23, 2027", "url": "https://www.stocktitan.net/sec-filings/SPRO/form-4-spero-therapeutics-inc-insider-trading-activity-462655122805.html", "source_name": "Stock Titan", "published_at": "2026-06-25T23:40:50", "published_display": "25 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics (SPRO) director receives RSU and stock option awards", "summary": "Spero Therapeutics director Kathleen Tregoning was granted 10,000 restricted stock units (RSUs) and stock options for 20,000 shares of common stock. The RSUs vest on June 23, 2027, and the stock options, with an exercise price of $2.1500 per share, also vest on June 23, 2027, and", "url": "https://www.stocktitan.net/sec-filings/SPRO/form-4-spero-therapeutics-inc-insider-trading-activity-15f47e57095f.html", "source_name": "Stock Titan", "published_at": "2026-06-25T23:40:50", "published_display": "25 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics (SPRO) Short Interest & Short Float | Updated Jun 2026", "summary": "As of June 15, 2026, Spero Therapeutics (SPRO) had a short interest of 1.83 million shares, representing 3.26% of its public float, marking a 7.33% increase from the previous report. The short interest ratio is 2.3 days to cover, indicating it would take 2.3 days to cover all sho", "url": "https://www.marketbeat.com/stocks/NASDAQ/SPRO/short-interest/", "source_name": "MarketBeat", "published_at": "2026-06-25T18:11:04", "published_display": "25 Jun 2026 18:11", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SPRO Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast and price target for Spero Therapeutics, Inc. (SPRO) stock, with analysts estimating a maximum price of $4.00. It also covers SPRO's current stock performance, volatility, market capitalization, earnings, and financial data. The information present", "url": "https://www.tradingview.com/symbols/NASDAQ-SPRO/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T14:40:50", "published_display": "25 Jun 2026 14:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equity awards to Spero (NASDAQ: SPRO) director Scott Jackson", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQbFV6NDl5V1VpR09VQWxsVTR3cU1SMUwzd1ByLS1PWVl2X0JYUEpCdGJjTmJxRlVRLWdJOHcxbUhySFFUUFRDVldEeDNVZDZ3UGUzSnZVMHdZSmVidFBqMDZ4YnhKWlVEN0I3NEdhUGFFZGNUX2l5T1RORjF2YVk5TUhOU214UExwb0FBQnlpdm40VHd1QlU4aWdORmIwTkJjLXFCQjRwaXB5cjVTdDFPTFk1d1I5eHc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics Stock: Antibiotic Development In Focus", "summary": "Spero Therapeutics (SPRO) is under scrutiny due to its antibiotic development programs and regulatory advancements in the field of infectious disease treatment. The company is primarily known for its clinical-stage efforts in developing treatments for infectious diseases. The pro", "url": "https://kalkinemedia.com/us/stocks/healthcare/spero-therapeutics-stock-antibiotic-development-in-focus", "source_name": "Kalkine Media", "published_at": "2026-06-18T18:40:18", "published_display": "18 Jun 2026 18:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics stock surges on FDA approval of Utebzi", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPRUw1WjNvcnp5dEphNEc4ZWRZNnZPbXd1NzdFbnpjSVJhbFVucXV0YlpxSTQ3OG14WGlnRFhGVXVtbU9qSllIMWQ4NElTTTNsUlZoZDItaDlaZW9EVVZHcHphaWZUakxPenZydnh6QXBGY1pYUFZXUDNYUC13bFhwaWlOd2xTaEtHZnZpM1dwOWpqSTgxRG90RmtETHdsRE12VXdDSTlleG1xeFN3VzBIRk9GczJVRVhwX0E0?oc=5", "source_name": "Investing.com", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Shares Jump After FDA Clears First Oral Carbapenem Antibiotic for U.S. Market (SPRO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxQSzVIUmVVLWZQTGFOaVhxNnVBMWhHSGp1OHA3aGEyTERrR1NUYWR2YlZMdW1EaURQdXkwUjlLVFhDVjl6NWxsblloMElkQlJOdTA2WWNRV1BxNW1TSXdqTjJuVVZiZWFzdW9PQU4tUE5zR0x1T1BfQXZlck5pWkZWTm1aT0tyamlsbllnVEo5N3BTbUU?oc=5", "source_name": "Market source", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics: Yesterday's Selloff On Utebzi Approval Seems Bewildering (NASDAQ:SPRO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQRVB4Y2JiY3BrZlVCUVljZFZGeDlRQlVtTVZYSzYtNFJJLWlMbGw3eFRZdGlad2RhbWVrOTA2dW9ERjNnZms2T1V5Z1Q5czM2QUZ6VmdVamRpTmUtQTZ6REwxc0U3eTk4Vzd2RXFaemhXd3FTOThRLXhaeDI1aUNJZWJIbnIyRHJZZEJHbUh1M2d4OUV0LVU4QzZrRXAyYUgyNE5vWUQzeWdubXNzeGNGci05SUx3QQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics Inc (SPRO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Spero Therapeutics Inc. (SPRO), detailing its business segments and regional revenue contributions. The company's revenue primarily comes from Collaboration Revenue Related Party (70.41%), Collaboration Revenue (18.84%), and Grant Rev", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-spro/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T23:10:27", "published_display": "17 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA approves first oral carbapenem for complicated UTIs in adults", "summary": "The FDA has approved Utebzi (tebipenem pivoxil) by Spero Therapeutics and GSK, making it the first oral carbapenem for treating complicated urinary tract infections (cUTIs), including pyelonephritis, in adults with limited oral treatment options. This approval is based on the PIV", "url": "https://www.stocktitan.net/news/SPRO/utebzi-tebipenem-pivoxil-approved-in-the-us-for-adults-with-l82czqzeufn6.html", "source_name": "Stock Titan", "published_at": "2026-06-17T16:10:27", "published_display": "17 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK, Spero Therapeutics Get FDA Approval for Utebzi in Complicated Urinary Tract Infections", "summary": "GSK and Spero Therapeutics have received FDA approval for Utebzi (tebipenem HBr) for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, in adults. This approval marks the first oral carbapenem antibiotic to be approved in the U.S. and offers a", "url": "https://www.moomoo.com/news/post/71676428/gsk-spero-therapeutics-get-fda-approval-for-utebzi-in-complicated", "source_name": "Moomoo", "published_at": "2026-06-17T16:10:27", "published_display": "17 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SPRO Stock Slumps As Volatility Grips Small-Cap Biotech", "summary": "Spero Therapeutics Inc. (SPRO) stock has fallen by 15.16% due to clinical and regulatory uncertainty, despite a strong cash position and minimal debt. The article highlights the stock's high volatility, with significant intraday price swings, making it attractive to active trader", "url": "https://www.timothysykes.com/news/spero-therapeutics-inc-spro-news-2026_06_17/", "source_name": "www.timothysykes.com", "published_at": "2026-06-17T15:32:05", "published_display": "17 Jun 2026 15:32", "sentiment": "negative", "sentiment_pct": 36, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "FDA to rule June 18 on Spero oral antibiotic for severe UTIs", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPUHR4TUthbWphaGYwQzJUdjZnYkhQVUREOWN4cEdOLXdzWlA2YWxIS0N4UnYtMDExTFFMRmVSOU5HczBabGhSSGJRQ2lnRUhOWnJTQnRiYXZqT3AxUUtaT3lSNlBwN3JGV3ZOcHV1Szl1U3ptVGowVDNndTNzMnR0WXZsTEVZMFJpYldXbm0zVG0zc2thWmY3Mnd6ZU1LekxmWms1M3l0NFladVJNT0pRTi1PaVVhTzZ6Q0NqTg?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Spero Therapeutics (SPRO) Earnings Turn Positive Challenging Bearish Profitability Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-28T07:00:00+00:00", "published_display": "28 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero\u2019s oral UTI antibiotic faces FDA decision on June 18", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPbjVQSFcyYm0wSV9XU2ZMeURtTmxaS1RHQ0hXNXJvbDd6bWdwaEg3T3ZYWGh3TWdFM1dKWVBHMVpYdGpNcU9HMUNoUTJ2SVllUHFRVWtUMTd6QnFUOFN1RGliTURtNTBzZENMbTc4SmhQenI4LWQ5WnZBZF9wNWxGdEI0cEdTNGJzaWJieWhVYUZjd1RGRkFrdEdVT0U0LXlONVBkeGZ3VHpZX1Y4MUlQbVpoRUM2bnRz?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trade Alert: CEO, CFO Of Spero Therapeutics Esther Rajavelu Has Sold Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxPWXZFYjd3Z1Vld0RLUVdZWE1sUHgtWEJodmtZTTNHOHIwOWhORGQ1V05xV01LdXFUNG12M1BmTDZRQkx2Y0dkWm1CZHNvaHhnLXdtdDQwVFEtLWpnS0JlZEp6LUZNS0thLWtlcWZmbDRRdkk0WjJUNDF0cmdSeEdRNVdkdlFVclppTXNzUk12SnlRclRmTG9VR3VpYnd5b1liTjFDd1F2RjFjWnV5LTdUSXN5ZHRCa3g4djlVdUhKSlFBX3VXZ2xzMklvQ1M1Z1daczl5VVhXbFJnazd0N3ZkTjAxXy0tOTDSAewBQVVfeXFMTmhnUE5WVGVTUTlFa21vNG9NTkxYZXFzQzgzMENZSW5NYXZLNkY2YjdaUU1oR05sR2lOd0MzYWxLLXp0SkRVWlNNcjJDRExpdUJZOExUWVJiTkVtQnlQa3FydHpHU3loVks1Mk5vZ0oxa0FZWXZxYTRBSDFrU2txZFNZVG40OENiSnVIVTJKUmQ0cTFzMG9nWFRTX3FhSHBTZm9xc0Vsb2NIS1pDejdVc0lBRWpsSWFraVotMEVxMFR2RHZ3TkQtV2x1b3pDWU1lQXJlWFozSzFld0ZjT1FYM0pleHFYcFNja1BXUzU?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-14T08:00:00+00:00", "published_display": "14 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics: Tebipenem\u2019s FDA Path Supports A Speculative Buy (NASDAQ:SPRO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNUUxkdk91Nnh2NWhYVDl5ZWdLSnFiemptcExudWNPMVN6WmZTdkdRVnhvbW5FM0ZKSHM5SXJ5bUI2bXpsdURQMWRrSVVxME9KS1RNS3JXQkdPSndrRWIxQzVjd18tNUdnSHVyZkwxM2Y3UDAzbnpmbFEwUTh0VTNfc0ZmQUZkT18yN0VWbVNzUU1IYWpmTlZncWhxYUFmQjdOQjVzeTNUQzVnQQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-02-11T08:00:00+00:00", "published_display": "11 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 26%", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-29T07:00:00+00:00", "published_display": "29 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Innovent licenses IBI355 rights to Spero for up to $1.1bn", "summary": "", "url": "https://finance.yahoo.com/m/4385de98-4d22-30fc-9295-2d9e6059552a/innovent-licenses-ibi355.html", "source_name": "Hospital Management", "published_at": "2026-07-15T10:01:36+00:00", "published_display": "15 Jul 2026 10:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals", "summary": "", "url": "https://finance.yahoo.com/m/a668a52a-493b-390d-b19c-26a9e84bfd61/j%26j-dips-despite-upbeat.html", "source_name": "BioPharma Dive", "published_at": "2026-07-15T09:18:00+00:00", "published_display": "15 Jul 2026 09:18", "sentiment": "negative", "sentiment_pct": 42, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics: \"Buy\" Utebzi Royalty Deal For Funding And SP001 In-Licensing (SPRO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOYWVTN1VXeFJsQ2ZVbktkcE8wZkhveGtMejQxbEdpX1ZPeUcweUNOaDlBajFvbnFqNlJMTlNlaXRZb1VkRGpwanpLN0dPQjVzSUVXcXIyN0ZGRDgyTW5SVkdoakM5N2dmX3kxYVlVUmxnelEyRmcyaHNjbDRRTUpEYWNDMTJNZlUxTm56OFRtbDdXTnZiamdsN0M1eW1JR3dRWHF6UUVFbzBodHd3a2xfbTlnNERlNFJ4a1E?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-14T17:40:33+00:00", "published_display": "14 Jul 2026 17:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero licenses anti-CD40L antibody from Innovent for $1.1bn", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNWTNwUjVJM3k4REcwT0Q5Rzh5VEJkOG4xYTZGWjRHb3lWd2prR1VMWkF6U3M0ajNXbE9zS0FEdTI4UnM4dmYzbTJwSFVGSU9fRERYUFdLdGJTUDMyd0VQZFFKbjRET3NUMkdQUWRZVmFlcTEwYy16MWNXSi12SXdydERlZEluSDhwU210SHRYWk9LYTFOeU9PNG9mZnp6N2pNb3ZzeW9JMU04UldGXzU3UENFaklqX19BUkVMajJmNWlidUZjeUxpSA?oc=5", "source_name": "Investing.com UK", "published_at": "2026-07-14T14:59:19+00:00", "published_display": "14 Jul 2026 14:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion", "summary": "Spero Therapeutics has licensed the rights to Innovent Biologics' experimental autoimmune disease treatment, IBI355, outside of Greater China in a deal potentially worth up to $1.1 billion. This agreement provides Spero with its first immunology asset, expanding beyond its infect", "url": "https://www.reuters.com/legal/litigation/spero-licenses-innovents-experimental-immune-disease-drug-up-11-billion-2026-07-14/", "source_name": "Reuters", "published_at": "2026-07-14T14:10:15", "published_display": "14 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero in-licenses Innovent\u2019s antibody therapy (SPRO:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOSENTeGlzOXRLMW1zS2FsT0dwZXB5UVVpaER0VlFqcmFvZm1mTG1tVFhhRHVjWkE4N3pxYm5mUlFFdVZEVGdWbjhXX25Lb2MtUUtFdmoyb1lxekFVaEc5SERiMHNvTDUyeFRnR0FicG9CclRLSGg2SFBEZHAwaXJoUmR6bEktWTVmdkE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-14T12:28:42+00:00", "published_display": "14 Jul 2026 12:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics (SPRO) Secures $105M Financing and $1.1B Licensing Agreement", "summary": "Spero Therapeutics (SPRO) announced a significant financing arrangement of $105 million with Healthcare Royalty and a licensing deal worth up to $1.1 billion with Innovent Biologics. These agreements aim to advance Spero's clinical programs, including the development of an antibo", "url": "https://www.gurufocus.com/news/8957684/spero-therapeutics-spro-secures-105m-financing-and-11b-licensing-agreement", "source_name": "GuruFocus", "published_at": "2026-07-14T13:10:15", "published_display": "14 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics (SPRO) Secures $105M Financing to Advance Immunology Development", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQZjRuc1NudFhGNUhTR1RmWE1LMEgwNUZuNU1WUnF0UGUtWHVLZU83cDB3VkE3SU9rUVRSUXFOSVNlSk45YmZuN1RKRlhFTGJoOHA3b2NKV0pBb2w4Mk1wdXh3TkhjeXUwaGY4dDhhMXpJLUtoX296U29tTk03azVkQU91RlVYX3hDVWtTbnZSSV9OcHg0SFI1cTZ2bDNrcUV5bmJYX3V3TFdEUGV0WUZyZWZjUXNMQlRoWl93?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-14T11:35:01+00:00", "published_display": "14 Jul 2026 11:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics (SPRO) Secures Exclusive License for SP001 Development", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPUG5HbU44TFhUNXk1clR5amZtUlRxQlhtbkhLb2RwMlBNNVR3dDRxZThhU1czMUFyc3o5SEhZc2k3dGNoOW1GRE1FbXFRZ3FZTUNEQXRoLUg4TDQ4cDhZdmktUW5feHVyTjVGRjJGQlBSakZPcHUwczdpYzdRSm14N3kwR0Vqd25yVjVqWXlRRlBQUEpuRmhGTm50N1lCc1V4OGRlY1Z4QnFxR2tqdG9V?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-14T11:35:01+00:00", "published_display": "14 Jul 2026 11:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics (SPRO) Secures Exclusive License for IBI355", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQdXJ5UlpsZjczUjBvZHNGcFd2OHNRaExTem4wV21sazhlQWUtZEhIUzVDbFpCc09ySmxsb0J6bE9TV2NKVmJ3MjVrWmctbVRVWGhCbWViekhkX1E0SG9GNWsxY3ZYdFFLT3ZqVDNJR3prbUNZTERHX2ZIU3JfaU1lNC1PNzRpZGhmd3pLQ0tHU2Q2NnV5UWVJbUFycll6ejNV?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-14T11:35:01+00:00", "published_display": "14 Jul 2026 11:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics Secures $105 Million Royalty Financing to Advance Immunology Pipeline", "summary": "Spero Therapeutics has secured $105 million in non-dilutive royalty financing from Healthcare Royalty (HCRx) to fund the clinical development of its lead immunology drug candidate, SP001. This financing, backed by future payments from its antibiotic Utebzi, enables Spero to exten", "url": "https://www.citybiz.co/article/873645/spero-therapeutics-secures-105-million-royalty-financing-to-advance-immunology-pipeline/", "source_name": "citybiz", "published_at": "2026-07-14T12:10:15", "published_display": "14 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics Licenses Immunology Drug Candidate From Innovent, Recieves $105 Million Financing", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/spero-therapeutics-licenses-immunology-drug-104640732.html", "source_name": "MT Newswires", "published_at": "2026-07-14T10:46:40+00:00", "published_display": "14 Jul 2026 10:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics Lands $105 Million Royalty Financing to Advance SP001 Development (SPRO)", "summary": "", "url": "https://finance.yahoo.com/m/9bb9d86a-52ae-3aef-bb4b-f7cd3fd578b3/spero-therapeutics-lands-%24105.html", "source_name": "InvestorsHub", "published_at": "2026-07-14T10:46:23+00:00", "published_display": "14 Jul 2026 10:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics Secures $105 Million Royalty Financing to Advance SP001 and Extend Cash Runway Through Second Half of 2029", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxPU2xmcmF2a2JwSWtNa2Z0WVRVOU4tdDc4NVJ6NFExbWpUZHZCMlZZaHlYTkVYcWFYeVc4RFgycnhxOW9CYVFmWDhHUFpDLTl3TFJORW9CdXZRcE5hQ1hVOEZ6cXM5bmdxRnBJdlBra0ZHdXgtZkZEUTZrbEpreDd5bWRydWhyaTJ0YmVpZ3pCRDBqWGxLZE5zZDNWNEVzX3A4bWxDdlVqNmZCMXpKRHhjS3NNbXZRTk9YbVpjckRNVEhXclZHd3NtcU4yRnhIMlRXMGNWVEIyeDNoSUpNRGw2ZkhJQnZGSFJNQ2RGMmtaUTRHQQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-14T10:12:00+00:00", "published_display": "14 Jul 2026 10:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/spero-therapeutics-announces-105-million-100200242.html", "source_name": "GlobeNewswire", "published_at": "2026-07-14T10:02:00+00:00", "published_display": "14 Jul 2026 10:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/innovent-biologics-spero-therapeutics-announce-100000421.html", "source_name": "PR Newswire", "published_at": "2026-07-14T10:00:00+00:00", "published_display": "14 Jul 2026 10:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics (Nasdaq: SPRO) inks SP001 deal and $105M royalty financing", "summary": "Spero Therapeutics has announced two significant financial and strategic moves: an exclusive worldwide licensing agreement (excluding Greater China) with Innovent Biologics for SP001, a third-generation Fc-silent anti-CD40L monoclonal antibody for which Spero paid a $35 million u", "url": "https://www.stocktitan.net/sec-filings/SPRO/8-k-spero-therapeutics-inc-reports-material-event-a86537e543f0.html", "source_name": "Stock Titan", "published_at": "2026-07-14T10:30:46", "published_display": "14 Jul 2026 10:30", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics shares fall after $105M KKR deal By Investing.com", "summary": "Spero Therapeutics shares dropped about 12% in pre-market trading after announcing a $105 million licensing agreement with affiliates of Healthcare Royalty, a KKR business. Under the deal, HCRx will receive a portion of future milestone and royalty payments from Utebzi sales, wit", "url": "https://ng.investing.com/news/stock-market-news/spero-therapeutics-shares-fall-after-105m-kkr-deal-93CH-2598306", "source_name": "Investing.com Nigeria", "published_at": "2026-07-14T10:24:46", "published_display": "14 Jul 2026 10:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics shares fall after $105M KKR deal", "summary": "Spero Therapeutics (SPRO) shares dropped by approximately 12% following the announcement of a $105 million licensing agreement with KKR's Healthcare Royalty business. Under the deal, HCRx will receive milestone and royalty payments from sales of Spero's drug Utebzi in exchange fo", "url": "https://www.investing.com/news/stock-market-news/spero-therapeutics-shares-fall-after-105m-kkr-deal-93CH-4790226", "source_name": "Investing.com", "published_at": "2026-07-14T10:10:15", "published_display": "14 Jul 2026 10:10", "sentiment": "negative", "sentiment_pct": 30, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero's $105M deal will support Phase 2 immunology drug SP001", "summary": "Spero Therapeutics has secured a $105 million non-recourse, non-dilutive royalty financing from Healthcare Royalty (HCRx) to fund the Phase 2 development of its lead immunology drug candidate, SP001. This financing, backed by a portion of future milestones and royalties from Uteb", "url": "https://www.stocktitan.net/news/SPRO/spero-therapeutics-announces-105-million-non-recourse-non-dilutive-yq6toa5chbcx.html", "source_name": "Stock Titan", "published_at": "2026-07-14T10:01:46", "published_display": "14 Jul 2026 10:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody", "summary": "Spero Therapeutics and Innovent Biologics have announced an exclusive licensing agreement for SP001 (IBI355), a third-generation anti-CD40L antibody. Spero receives global rights excluding Greater China and plans to initiate a Phase 2 trial for IgG4-related disease in Q2 2027. In", "url": "https://www.globenewswire.com/news-release/2026/07/14/3326657/0/en/spero-therapeutics-and-innovent-biologics-announce-exclusive-license-for-sp001-ibi355-a-phase-2-ready-third-generation-anti-cd40l-antibody.html", "source_name": "GlobeNewswire", "published_at": "2026-07-14T09:59:46", "published_display": "14 Jul 2026 09:59", "sentiment": "positive", "sentiment_pct": 94, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cambridge biotech strikes $1.1B deal with Chinese partner, shifts to immunology", "summary": "Cambridge-based Spero Therapeutics has signed a $1.1 billion drug deal with Chinese partner Innovent Biologics. This agreement will enable Spero to shift its strategic focus towards immunology. The company is leveraging proceeds from a recent drug approval to fund this new direct", "url": "https://www.bizjournals.com/boston/news/2026/07/14/spero-innovent-immunology-deal.html", "source_name": "The Business Journals", "published_at": "2026-07-14T09:59:46", "published_display": "14 Jul 2026 09:59", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Spero Therapeutics, Inc. \u2013 MUN:2HA", "summary": "This article provides financial data for Spero Therapeutics, Inc. (MUN:2HA), specifically focusing on its enterprise value to EBIT forward. It indicates that the market was closed with no trades at the time of publication. The content is presented within the TradingView platform,", "url": "https://www.tradingview.com/symbols/MUN-2HA/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T20:10:43", "published_display": "12 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics outlines its antibiotic pipeline as investors track regulatory progress", "summary": "Spero Therapeutics is a clinical-stage biopharmaceutical company focusing on novel antibiotic candidates for multidrug-resistant bacterial infections. The company's strategy involves progressing assets through clinical trials, considering potential collaborations, and navigating ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/spero-therapeutics-outlines-its-antibiotic-pipeline-as-investors-track/69716226", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T17:42:36", "published_display": "07 Jul 2026 17:42", "sentiment": "positive", "sentiment_pct": 67, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kailera Therapeutics Appoints Kathleen\u00a0Tregoning as Chief Corporate Affairs Officer", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/kailera-therapeutics-appoints-kathleen-tregoning-113000007.html", "source_name": "GlobeNewswire", "published_at": "2026-06-29T11:30:00+00:00", "published_display": "29 Jun 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics, Inc. Actuals & Estimates (NASDAQ:SPRO)", "summary": "This article provides an overview of Spero Therapeutics, Inc. (SPRO) stock, including its current price, historical performance, analyst forecasts, and key financial metrics. It highlights recent stock changes, market capitalization, upcoming earnings, and past financial results,", "url": "https://www.tradingview.com/symbols/NASDAQ-SPRO/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T16:10:41", "published_display": "26 Jun 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics, Inc. Actuals & Estimates (BOATS:SPRO)", "summary": "This article provides financial actuals and estimates for Spero Therapeutics, Inc. (SPRO), including analyst forecasts, historical price data, earnings reports, and other key financial metrics. It highlights that analysts expect a maximum and minimum price of $4.00, and the compa", "url": "https://www.tradingview.com/symbols/BOATS-SPRO/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T08:40:59", "published_display": "26 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics (NASDAQ: SPRO) doubles share authorization and adopts 2026 stock plan", "summary": "Spero Therapeutics' stockholders approved a new 2026 Stock Incentive Plan covering up to 12,895,866 shares and doubled the authorized common stock from 120,000,000 to 240,000,000 shares. These actions provide the company with greater flexibility for future equity awards and poten", "url": "https://www.stocktitan.net/sec-filings/SPRO/8-k-spero-therapeutics-inc-reports-material-event-38630813b4e4.html", "source_name": "Stock Titan", "published_at": "2026-06-26T05:40:56", "published_display": "26 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics (SPRO) grants director RSUs and 20,000 stock options", "summary": "Spero Therapeutics director Frank E. Thomas received equity awards comprising 10,000 restricted stock units (RSUs) and options to purchase 20,000 shares of common stock at an exercise price of $2.15 per share. Both the RSUs and options are set to vest on June 23, 2027, contingent", "url": "https://www.stocktitan.net/sec-filings/SPRO/form-4-spero-therapeutics-inc-insider-trading-activity-13ea138c3d4e.html", "source_name": "Stock Titan", "published_at": "2026-06-26T04:09:49", "published_display": "26 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics (SPRO) director receives RSU and 20,000-share option grant", "summary": "Spero Therapeutics director John C. Pottage Jr. was granted 10,000 restricted stock units (RSUs) and a stock option for 20,000 shares, as detailed in a recent Form 4 filing. The RSUs and stock options are set to vest on June 23, 2027, contingent upon his continued service as a di", "url": "https://www.stocktitan.net/sec-filings/SPRO/form-4-spero-therapeutics-inc-insider-trading-activity-63463829320b.html", "source_name": "Stock Titan", "published_at": "2026-06-26T04:09:49", "published_display": "26 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Spero Therapeutics Inc For: 25 June By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Spero Therapeutics Inc. related to activity on June 25th. It is a brief, factual announcement without further details provided within the content. The article primarily serves as a placeholder for a financial filing a", "url": "https://uk.investing.com/news/stock-market-news/form-4-spero-therapeutics-inc-for-25-june-93CH-4745517", "source_name": "Investing.com UK", "published_at": "2026-06-26T00:02:00", "published_display": "26 Jun 2026 00:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics (SPRO) director awarded RSUs and stock options", "summary": "Spero Therapeutics director Patrick V.J.J. Vink was granted 10,000 restricted stock units (RSUs) and options for 20,000 shares, as detailed in a recent SEC Form 4 filing. The RSUs and stock options vest on June 23, 2027, with the options having an exercise price of $2.15 per shar", "url": "https://www.stocktitan.net/sec-filings/SPRO/form-4-spero-therapeutics-inc-insider-trading-activity-a043c72cc825.html", "source_name": "Stock Titan", "published_at": "2026-06-25T23:40:50", "published_display": "25 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics (SPRO) director receives 10,000 RSUs and 20,000-share option grant", "summary": "Spero Therapeutics director Cynthia Smith was granted 10,000 Restricted Stock Units (RSUs) and a stock option for 20,000 shares of common stock. These equity awards, with an exercise price of $2.15 per share for the options, are compensation-related and will vest on June 23, 2027", "url": "https://www.stocktitan.net/sec-filings/SPRO/form-4-spero-therapeutics-inc-insider-trading-activity-462655122805.html", "source_name": "Stock Titan", "published_at": "2026-06-25T23:40:50", "published_display": "25 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics (SPRO) director receives RSU and stock option awards", "summary": "Spero Therapeutics director Kathleen Tregoning was granted 10,000 restricted stock units (RSUs) and stock options for 20,000 shares of common stock. The RSUs vest on June 23, 2027, and the stock options, with an exercise price of $2.1500 per share, also vest on June 23, 2027, and", "url": "https://www.stocktitan.net/sec-filings/SPRO/form-4-spero-therapeutics-inc-insider-trading-activity-15f47e57095f.html", "source_name": "Stock Titan", "published_at": "2026-06-25T23:40:50", "published_display": "25 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics (SPRO) Short Interest & Short Float | Updated Jun 2026", "summary": "As of June 15, 2026, Spero Therapeutics (SPRO) had a short interest of 1.83 million shares, representing 3.26% of its public float, marking a 7.33% increase from the previous report. The short interest ratio is 2.3 days to cover, indicating it would take 2.3 days to cover all sho", "url": "https://www.marketbeat.com/stocks/NASDAQ/SPRO/short-interest/", "source_name": "MarketBeat", "published_at": "2026-06-25T18:11:04", "published_display": "25 Jun 2026 18:11", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SPRO Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast and price target for Spero Therapeutics, Inc. (SPRO) stock, with analysts estimating a maximum price of $4.00. It also covers SPRO's current stock performance, volatility, market capitalization, earnings, and financial data. The information present", "url": "https://www.tradingview.com/symbols/NASDAQ-SPRO/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T14:40:50", "published_display": "25 Jun 2026 14:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equity awards to Spero (NASDAQ: SPRO) director Scott Jackson", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQbFV6NDl5V1VpR09VQWxsVTR3cU1SMUwzd1ByLS1PWVl2X0JYUEpCdGJjTmJxRlVRLWdJOHcxbUhySFFUUFRDVldEeDNVZDZ3UGUzSnZVMHdZSmVidFBqMDZ4YnhKWlVEN0I3NEdhUGFFZGNUX2l5T1RORjF2YVk5TUhOU214UExwb0FBQnlpdm40VHd1QlU4aWdORmIwTkJjLXFCQjRwaXB5cjVTdDFPTFk1d1I5eHc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics Stock: Antibiotic Development In Focus", "summary": "Spero Therapeutics (SPRO) is under scrutiny due to its antibiotic development programs and regulatory advancements in the field of infectious disease treatment. The company is primarily known for its clinical-stage efforts in developing treatments for infectious diseases. The pro", "url": "https://kalkinemedia.com/us/stocks/healthcare/spero-therapeutics-stock-antibiotic-development-in-focus", "source_name": "Kalkine Media", "published_at": "2026-06-18T18:40:18", "published_display": "18 Jun 2026 18:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics stock surges on FDA approval of Utebzi", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPRUw1WjNvcnp5dEphNEc4ZWRZNnZPbXd1NzdFbnpjSVJhbFVucXV0YlpxSTQ3OG14WGlnRFhGVXVtbU9qSllIMWQ4NElTTTNsUlZoZDItaDlaZW9EVVZHcHphaWZUakxPenZydnh6QXBGY1pYUFZXUDNYUC13bFhwaWlOd2xTaEtHZnZpM1dwOWpqSTgxRG90RmtETHdsRE12VXdDSTlleG1xeFN3VzBIRk9GczJVRVhwX0E0?oc=5", "source_name": "Investing.com", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Shares Jump After FDA Clears First Oral Carbapenem Antibiotic for U.S. Market (SPRO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxQSzVIUmVVLWZQTGFOaVhxNnVBMWhHSGp1OHA3aGEyTERrR1NUYWR2YlZMdW1EaURQdXkwUjlLVFhDVjl6NWxsblloMElkQlJOdTA2WWNRV1BxNW1TSXdqTjJuVVZiZWFzdW9PQU4tUE5zR0x1T1BfQXZlck5pWkZWTm1aT0tyamlsbllnVEo5N3BTbUU?oc=5", "source_name": "Market source", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics: Yesterday's Selloff On Utebzi Approval Seems Bewildering (NASDAQ:SPRO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQRVB4Y2JiY3BrZlVCUVljZFZGeDlRQlVtTVZYSzYtNFJJLWlMbGw3eFRZdGlad2RhbWVrOTA2dW9ERjNnZms2T1V5Z1Q5czM2QUZ6VmdVamRpTmUtQTZ6REwxc0U3eTk4Vzd2RXFaemhXd3FTOThRLXhaeDI1aUNJZWJIbnIyRHJZZEJHbUh1M2d4OUV0LVU4QzZrRXAyYUgyNE5vWUQzeWdubXNzeGNGci05SUx3QQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics Inc (SPRO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Spero Therapeutics Inc. (SPRO), detailing its business segments and regional revenue contributions. The company's revenue primarily comes from Collaboration Revenue Related Party (70.41%), Collaboration Revenue (18.84%), and Grant Rev", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-spro/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T23:10:27", "published_display": "17 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA approves first oral carbapenem for complicated UTIs in adults", "summary": "The FDA has approved Utebzi (tebipenem pivoxil) by Spero Therapeutics and GSK, making it the first oral carbapenem for treating complicated urinary tract infections (cUTIs), including pyelonephritis, in adults with limited oral treatment options. This approval is based on the PIV", "url": "https://www.stocktitan.net/news/SPRO/utebzi-tebipenem-pivoxil-approved-in-the-us-for-adults-with-l82czqzeufn6.html", "source_name": "Stock Titan", "published_at": "2026-06-17T16:10:27", "published_display": "17 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK, Spero Therapeutics Get FDA Approval for Utebzi in Complicated Urinary Tract Infections", "summary": "GSK and Spero Therapeutics have received FDA approval for Utebzi (tebipenem HBr) for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, in adults. This approval marks the first oral carbapenem antibiotic to be approved in the U.S. and offers a", "url": "https://www.moomoo.com/news/post/71676428/gsk-spero-therapeutics-get-fda-approval-for-utebzi-in-complicated", "source_name": "Moomoo", "published_at": "2026-06-17T16:10:27", "published_display": "17 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SPRO Stock Slumps As Volatility Grips Small-Cap Biotech", "summary": "Spero Therapeutics Inc. (SPRO) stock has fallen by 15.16% due to clinical and regulatory uncertainty, despite a strong cash position and minimal debt. The article highlights the stock's high volatility, with significant intraday price swings, making it attractive to active trader", "url": "https://www.timothysykes.com/news/spero-therapeutics-inc-spro-news-2026_06_17/", "source_name": "www.timothysykes.com", "published_at": "2026-06-17T15:32:05", "published_display": "17 Jun 2026 15:32", "sentiment": "negative", "sentiment_pct": 36, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA to rule June 18 on Spero oral antibiotic for severe UTIs", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPUHR4TUthbWphaGYwQzJUdjZnYkhQVUREOWN4cEdOLXdzWlA2YWxIS0N4UnYtMDExTFFMRmVSOU5HczBabGhSSGJRQ2lnRUhOWnJTQnRiYXZqT3AxUUtaT3lSNlBwN3JGV3ZOcHV1Szl1U3ptVGowVDNndTNzMnR0WXZsTEVZMFJpYldXbm0zVG0zc2thWmY3Mnd6ZU1LekxmWms1M3l0NFladVJNT0pRTi1PaVVhTzZ6Q0NqTg?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics (SPRO) Earnings Turn Positive Challenging Bearish Profitability Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-28T07:00:00+00:00", "published_display": "28 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero\u2019s oral UTI antibiotic faces FDA decision on June 18", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPbjVQSFcyYm0wSV9XU2ZMeURtTmxaS1RHQ0hXNXJvbDd6bWdwaEg3T3ZYWGh3TWdFM1dKWVBHMVpYdGpNcU9HMUNoUTJ2SVllUHFRVWtUMTd6QnFUOFN1RGliTURtNTBzZENMbTc4SmhQenI4LWQ5WnZBZF9wNWxGdEI0cEdTNGJzaWJieWhVYUZjd1RGRkFrdEdVT0U0LXlONVBkeGZ3VHpZX1Y4MUlQbVpoRUM2bnRz?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trade Alert: CEO, CFO Of Spero Therapeutics Esther Rajavelu Has Sold Stock", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-14T08:00:00+00:00", "published_display": "14 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics: Tebipenem\u2019s FDA Path Supports A Speculative Buy (NASDAQ:SPRO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNUUxkdk91Nnh2NWhYVDl5ZWdLSnFiemptcExudWNPMVN6WmZTdkdRVnhvbW5FM0ZKSHM5SXJ5bUI2bXpsdURQMWRrSVVxME9KS1RNS3JXQkdPSndrRWIxQzVjd18tNUdnSHVyZkwxM2Y3UDAzbnpmbFEwUTh0VTNfc0ZmQUZkT18yN0VWbVNzUU1IYWpmTlZncWhxYUFmQjdOQjVzeTNUQzVnQQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-02-11T08:00:00+00:00", "published_display": "11 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 26%", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-29T07:00:00+00:00", "published_display": "29 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 98, "total_relevant": 59, "sentiment_summary": {"positive": 15, "negative": 6, "neutral": 38, "score": 54, "total": 59, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 16.65, "count": 29}, {"event": "earnings", "label": "Earnings", "weight": 6.05, "count": 13}, {"event": "deals", "label": "Deals and strategy", "weight": 5.1, "count": 8}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 3.65, "count": 6}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 15, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 2.1, "latest_week": "2026-07-10", "one_week_move": -4.5, "four_week_move": -26.3, "twelve_week_move": -23.6, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.060008, "market_dynamics_buy_signal": false, "relative_strength": -23.292035, "fair_value_gap": 25.5, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 39.6044, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-4.5% over one week, -26.3% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 12}, {"label": "Market source", "count": 6}, {"label": "TradingView", "count": 5}, {"label": "simplywall.st", "count": 5}, {"label": "Seeking Alpha", "count": 4}, {"label": "GuruFocus", "count": 4}, {"label": "GlobeNewswire", "count": 3}, {"label": "Investing.com UK", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 51}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 29}, {"label": "Earnings", "count": 13}, {"label": "Deals and strategy", "count": 8}, {"label": "Regulatory and legal", "count": 6}, {"label": "Balance sheet", "count": 2}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "51", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "5", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-4.5% over one week, -26.3% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Innovent licenses IBI355 rights to Spero for up to $1.1bn"}], "updated_at": "2026-07-16T03:02:22.183641+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}